RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD

A Phase 1b Dose-escalating Study With RBT-1, in Healthy Volunteers and Subjects With Chronic Kidney Disease Stage 3b-4

A Phase 1b study to evaluate the safety, tolerability and pharmacodynamic effect of RBT-1 in healthy volunteers and subjects with stage 3b-4 CKD.

Study Overview

• Status: Withdrawn
• Conditions: Acute Kidney Injury
• Intervention / Treatment: Drug: FeS and SnPP

Detailed Description

This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with stage 3b-4 CKD. The following biomarkers will be used as surrogate measures of protective activity: Haptoglobin, Ferritin, Bilirubin, Hemopexin, IL-10, and Heme Oxygenase-1. Additionally, the P21 biomarker will be monitored at various points of the study.

• Study Type: Interventional
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male and female subjects age 18 to 80 years (inclusive, at time of ICF).
2. Body weight <125 kg.
3. Able and willing to comply with all study procedures.

4. Female subjects must be either post-menopausal for at least 1 year or surgically sterile (tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until 28 days after study drug administration.

   Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until 28 days after study drug administration. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation.

5. CKD as determined by estimated glomerular filtration rate (GFR) between 15-45 ml/min as estimated using the CKD-EPI equation (CKD class 3b-4). -

Exclusion Criteria:

1. History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer or non-melanoma skin cancers.
2. Use of investigational drugs or participation in another clinical trial within 30 days or 5 half-lives prior to screening, whichever is longer.
3. Serum ferritin > 500 ng/ml or who have received IV iron within 28 days of screening, or currently being treated with oral iron.
4. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study.
5. Regular use of drugs of abuse and/or positive findings on urinary drug screening.
6. Current tobacco use and/or positive findings on urinary cotinine screening.
7. Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects' tasks associated with the protocol.
8. Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.
9. Known hypersensitivity or previous anaphylaxis to RBT-1 or to components thereof. -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Administer a dose 12mgFeS/9mg SnPP; 12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.	Drug: FeS and SnPP; Escalating doses of drug will be compared for biomarker changes; Other Names: FeS (Iron Sucrose) SnPP (Stannous Protoporpyhrin
Other: Administer a dose 60mgFeS/45 mg SnPP; 12 healthy volunteers will be administered a single dose of 60 mg of Iron Sucrose and 45 mg of Stannous Protoporphyrin and followed for seven days.	Drug: FeS and SnPP; Escalating doses of drug will be compared for biomarker changes; Other Names: FeS (Iron Sucrose) SnPP (Stannous Protoporpyhrin
Other: Administer a dose 120mgFeS/90mg SnPP; 12 healthy volunteers will be administered a single dose of 120 mg of Iron Sucrose and 90 mg of Stannous Protoporphyrin and followed for seven days.	Drug: FeS and SnPP; Escalating doses of drug will be compared for biomarker changes; Other Names: FeS (Iron Sucrose) SnPP (Stannous Protoporpyhrin
Other: Administer a dose 180mgFeS/135mg SnPP; 12 healthy volunteers will be administered a single dose of 180 mg and 135 mg of Stannous Protoporphyrin and followed for seven days.	Drug: FeS and SnPP; Escalating doses of drug will be compared for biomarker changes; Other Names: FeS (Iron Sucrose) SnPP (Stannous Protoporpyhrin
Other: Administer a dose of FeS/SnPP CKD Arm; 12 subjects with stage 3 or 4 CKD will be administered a single dose of Iron Sucrose and Stannous Protoporphyrin selected from the highest dose from the prior arm that evidences the best safety profile. The subjects will be followed for seven days.	Drug: FeS and SnPP; Escalating doses of drug will be compared for biomarker changes; Other Names: FeS (Iron Sucrose) SnPP (Stannous Protoporpyhrin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of RBT-1 on biomarkers of cytoprotective activity	Measuring Haptoglobin, Ferritin, Bilirubin, Hemopexin, IL-10, and Heme Oxygenase-1, the P21 biomarker systemic levels	7 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	Safety and tolerability of RBT-1 in Healthy Volunteers and subjects with CKD	7 days
Establish the optimal dose for future development	The highest dose of RBT-1 with the best safety and tolerability will be determined	60 days

Collaborators and Investigators

• Sponsor: Renibus Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Anticipated): September 15, 2018
• Primary Completion (Anticipated): November 30, 2018
• Study Completion (Anticipated): March 31, 2019

Study Registration Dates

• First Submitted: August 7, 2018
• First Submitted That Met QC Criteria: August 10, 2018
• First Posted (Actual): August 14, 2018

Study Record Updates

• Last Update Posted (Actual): May 11, 2020
• Last Update Submitted That Met QC Criteria: May 8, 2020
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency; Acute Kidney Injury; Hematinics; Ferric Oxide, Saccharated
• Other Study ID Numbers: REN-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No